NASDAQ · SPRO
Healthcare · Biotechnology
$1.17
Down-$0.02 (-1.68%)
Updated Oct 8, 2026, 4:55 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SPRO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
SPRO closed at $1.17 after 21 trading sessions, up 0.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.19 | $1.19 | $1.16 | $1.17 | 236.67K |
| Oct 6, 2026 | $1.21 | $1.236 | $1.18 | $1.19 | 347.57K |
| Oct 5, 2026 | $1.17 | $1.20 | $1.15 | $1.16 | 942.72K |
| Oct 2, 2026 | $1.26 | $1.266 | $1.1705 | $1.19 | 906.92K |
| Oct 1, 2026 | $1.22 | $1.31 | $1.195 | $1.26 | 1.04M |
| Sep 30, 2026 | $1.21 | $1.29 | $1.20 | $1.21 | 558.21K |
| Sep 29, 2026 | $1.20 | $1.22 | $1.17 | $1.20 | 334.91K |
| Sep 28, 2026 | $1.22 | $1.22 | $1.175 | $1.19 | 393.26K |
| Sep 25, 2026 | $1.27 | $1.29 | $1.21 | $1.23 | 542.77K |
| Sep 24, 2026 | $1.25 | $1.29 | $1.24 | $1.25 | 476.93K |
| Sep 23, 2026 | $1.36 | $1.3977 | $1.24 | $1.26 | 1.4M |
| Sep 22, 2026 | $1.30 | $1.44 | $1.28 | $1.36 | 7.76M |
| Sep 21, 2026 | $1.14 | $1.15 | $1.12 | $1.14 | 319.1K |
| Sep 18, 2026 | $1.12 | $1.21 | $1.115 | $1.13 | 501.37K |
| Sep 17, 2026 | $1.14 | $1.14 | $1.114 | $1.12 | 181.77K |
| Sep 16, 2026 | $1.12 | $1.14 | $1.10 | $1.11 | 439.64K |
| Sep 15, 2026 | $1.14 | $1.151 | $1.11 | $1.13 | 225.28K |
| Sep 14, 2026 | $1.13 | $1.16 | $1.13 | $1.14 | 267.14K |
| Sep 11, 2026 | $1.13 | $1.15 | $1.13 | $1.13 | 310.63K |
| Sep 10, 2026 | $1.18 | $1.18 | $1.12 | $1.12 | 569.29K |
| Sep 9, 2026 | $1.20 | $1.21 | $1.17 | $1.17 | 367.06K |
The latest Smart Investors Daily articles mentioning SPRO.
Company
Market Activity
Research & News
SPRO research
Company profile and research snapshot.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 20, 2024 | Evercore ISI Group | In-Line | — |
| Dec 2, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 18, 2024 | TD Cowen | Hold | — |
No generated briefing is available yet.
Benzinga · May 13, 2026
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 48 percent increase over losses of $(0.25) per share from
Finnhub · May 13, 2026
New Drug Application for tebipenem HBr for complicated urinary tract infections , including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its cash runway...
SeekingAlpha · Feb 11, 2026
Spero Therapeuticsâ oral antibiotic tebipenem shows Phase 3 success and supports GSKâs NDA resubmission. Click here to read my latest analysis of SPRO stock.
GlobeNewswire Inc. · Nov 28, 2025
Spero Therapeutics granted 90,000 restricted stock unit awards to a new employee under their 2019 Inducement Equity Incentive Plan, with vesting occurring in four equal annual installments starting December 1, 2025.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRO.
